PMID- 22825335
OWN - NLM
STAT- MEDLINE
DCOM- 20130411
LR  - 20211021
IS  - 1555-8576 (Electronic)
IS  - 1538-4047 (Print)
IS  - 1538-4047 (Linking)
VI  - 13
IP  - 11
DP  - 2012 Sep
TI  - pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a 
      tissue-microarray study with clinic-pathological correlations.
PG  - 967-77
LID - 10.4161/cbt.20991 [doi]
AB  - The EGFR (epidermal growth factor receptor) a member of the family of 
      transmembrane protein kinase receptors known as the erbB family shows a 
      significant correlation with the presence of metastases and poorly differentiated 
      oral cancer. Aim of the present work is to define the key-role of EGFR in oral 
      cancer prognosis. We have analyzed the EGFR expression on 149 cases of oral 
      squamous cell cancers (OSCC) and we have found that it was poorly expressed in 
      normal oral epithelium, but its expression was significantly increased in OSCCs. 
      Moreover, we have recorded that both pEGFR-Tyr 845 and pEGFR-Tyr 1068 were mainly 
      distributed in high histological grading and in advanced stages. Western blotting 
      has confirmed the total absence of EGFR phosphorylation in normal oral epithelium 
      and the higher level of protein phosphorylation in representative cases of OSCCs. 
      The EGF-R amplification was found by fluorescence in situ hybridization (FISH) in 
      14% of OSCC; interestingly, EGF-R amplification was mainly observed in OSCC with 
      higher histological grading (G2 and G3) and advanced stage (pT4) sub-groups. 
      Kaplan-Meyer survival analysis suggested that patients with positive pEGFR-Tyr 
      845 tumors had a worse prognosis and were bad responders to chemotherapy. These 
      results confirm the central role of EGF-R activation status as a prognostic 
      biomarker in OSCC.
FAU - Aquino, Gabriella
AU  - Aquino G
AD  - Section of Pathological Anatomy, Fourth Section of Maxillofacial Surgery, 
      Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G.Pascale, 
      Naples, Italy.
FAU - Pannone, Giuseppe
AU  - Pannone G
FAU - Santoro, Angela
AU  - Santoro A
FAU - Liguori, Giuseppina
AU  - Liguori G
FAU - Franco, Renato
AU  - Franco R
FAU - Serpico, Rosario
AU  - Serpico R
FAU - Florio, Gianluca
AU  - Florio G
FAU - De Rosa, Alfredo
AU  - De Rosa A
FAU - Mattoni, Marilena
AU  - Mattoni M
FAU - Cozza, Valentina
AU  - Cozza V
FAU - Botti, Gerardo
AU  - Botti G
FAU - Losito, Simona
AU  - Losito S
FAU - Longo, Francesco
AU  - Longo F
FAU - Staibano, Stefania
AU  - Staibano S
FAU - Cuda, Giovanni
AU  - Cuda G
FAU - Lo Muzio, Lorenzo
AU  - Lo Muzio L
FAU - Sbordone, Carolina
AU  - Sbordone C
FAU - Bufo, Pantaleo
AU  - Bufo P
FAU - Grimaldi, Anna
AU  - Grimaldi A
FAU - Caraglia, Michele
AU  - Caraglia M
FAU - Di Domenico, Marina
AU  - Di Domenico M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120724
PL  - United States
TA  - Cancer Biol Ther
JT  - Cancer biology & therapy
JID - 101137842
RN  - 42HK56048U (Tyrosine)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*enzymology/genetics/pathology
MH  - ErbB Receptors/*biosynthesis/genetics/metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Mouth Neoplasms/*enzymology/genetics/pathology
MH  - Neoplasm Staging
MH  - Paraffin Embedding
MH  - Phosphorylation
MH  - Prognosis
MH  - Retrospective Studies
MH  - Tissue Array Analysis
MH  - Tyrosine/genetics/metabolism
PMC - PMC3461819
EDAT- 2012/07/25 06:00
MHDA- 2013/04/12 06:00
PMCR- 2013/09/01
CRDT- 2012/07/25 06:00
PHST- 2012/07/25 06:00 [entrez]
PHST- 2012/07/25 06:00 [pubmed]
PHST- 2013/04/12 06:00 [medline]
PHST- 2013/09/01 00:00 [pmc-release]
AID - 20991 [pii]
AID - 2012CBT5600R [pii]
AID - 10.4161/cbt.20991 [doi]
PST - ppublish
SO  - Cancer Biol Ther. 2012 Sep;13(11):967-77. doi: 10.4161/cbt.20991. Epub 2012 Jul 
      24.